Axsome Therapeutics Inc (GB:0HKF)

Axsome Therapeutics (0HKF) Income Statement


Axsome Therapeutics Income Statement

Last quarter (Q1 2023), Axsome Therapeutics's total revenue was $94.58M, an increase of Infinity% from the same quarter last year. In Q1, Axsome Therapeutics's net income was $-11.22M. See Axsome Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 144.61M$ 50.04M$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
$ 6.95M$ 3.30M----
Gross Profit
$ 137.67M$ 46.74M----
Operating Expense
$ 358.82M$ 221.34M$ 124.71M$ 99.09M$ 67.11M$ 32.63M
Operating Income
$ -144.57M$ -174.60M$ -124.71M$ -99.09M$ -67.11M$ -32.63M
Net Non Operating Interest Income Expense
$ -8.26M$ -7.33M$ -5.70M$ -2.57M$ -1.24M$ -1.13M
Other Income Expense
$ -51.76M$ -51.67M-$ -1.25M-$ 2.79M
Pretax Income
$ -150.94M$ -181.94M$ -130.40M$ -102.90M$ -68.35M$ -30.97M
Tax Provision
$ 2.58M-----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -158.72M$ -187.13M$ -130.40M$ -102.90M$ -68.35M$ -30.97M
Basic EPS
$ -4.86$ -4.60$ -3.47$ -2.77$ -2.01$ -1.15
Diluted EPS
$ -3.83$ -4.60$ -3.47$ -2.77$ -2.01$ -1.15
Basic Average Shares
$ 164.97M$ 40.66M$ 37.62M$ 37.21M$ 34.02M$ 26.88M
Diluted Average Shares
$ 164.97M$ 40.66M$ 37.62M$ 37.21M$ 34.02M$ 26.88M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 365.76M$ 224.64M$ 124.71M$ 99.09M$ 67.11M$ 32.63M
Net Income From Continuing And Discontinued Operation
$ -158.72M$ -187.13M$ -130.40M$ -102.90M$ -68.35M$ -30.97M
Normalized Income
$ -87.16M-$ -130.40M$ -101.65M$ -68.35M$ -33.76M
Interest Expense
$ 4.67M-$ 5.70M$ 2.57M$ 1.24M$ 1.13M
$ -142.69M$ -174.60M$ -124.71M$ -100.33M$ -67.11M$ -29.84M
$ -136.27M$ -170.46M$ -123.55M$ -100.26M$ -67.07M$ -29.79M
Currency in USD

Axsome Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis